Volume : 11, Issue : 12, December – 2024

Title:

METHOD DEVELOPMENT AND VALIDATION FOR SIMULTANEOUS ESTIMATION OF ATORVASTATIN, EZETIMIBEIN AND FENOFIBRATE BULK AND PHARMACEUTICAL DOSAGE FORMS BY RP-HPLC

Authors :

M.Arjun, M.Chaitanya, P.Aravindra Reddy

Abstract :

RP-HPLC method was developed and validated as per ICH guidelines for the estimation of. Atorvastatin, Ezetimibe and Fenofibrate Simultaneous Estimation of Atorvastatin, and Ezetimibe were carried out by RP- HPLC using potassium dihydrogen orthophosphate buffer & acetonitrile, and C18 G analytical columnas a stationary phase and peak was observed at 265 nm which was selected as a wavelength for quantitative estimation. After the development of the method, it was validated for various parameters. It was found that recovery value of pure drug was between 99 % to 101% which indicates that the method is accurate and also reveals that commonly used excipients and additives present in the pharmaceutical formulations were not interfering in the proposed methods. The ruggedness of the method was checked by different analysts and found that the results were nearly same which indicates that the method is rugged. Based on the results observed, it was concluded that proposed method can be used for routine analysis of Atorvastatin , Ezetimibe and Fenofibrate Key words: Atorvastatin and Ezetimibe, Fenofibrate ,linearity, accuracy, precision.

Cite This Article:

Please cite this article in press M.Chaitanya et al Method Development And Validation For Simultaneous Estimation Of Atorvastatin, Ezetimibein And Fenofibrate Bulk And Pharmaceutical Dosage Forms By Rp-Hplc.,Indo Am. J. P. Sci, 2024; 11 (12)

Number of Downloads : 10

References:

1. Collins R, Armitage J, Parish S. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 2002; 360:7-22.
2. Genest J, Pherson RMc, Frolich J, Anderson T, Campbell N, Carpentier A, et al. Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult recommendations. Canadian Journal of Cardiology. 2009; 25(10):567- 579.
3. Knopp RH, Gitter H, Truitt T, Bays H, Manion CV, Lipka LJ, et al. Ezetimibe Study Group. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. European Heart Journal. 2003; 24:729-741.
4. Kosoglou T, Statkevich P, Fruchart JC. Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibe. Current Medical Research and Opinion. 2004; 20:1197-1207.
5. Ramjattan BR, Callaghan DJG, Theiss U. Efficacy and tolerability of a “suprabioavailable” formulation of fenofibrate in patients with dyslipidemia: A pooled analysis of two open-label trials. Clinical Therapeutics Journal. 2002; 24:1105-1116.
6. Sujana SK, Lahey KA, Day A, LaHaye SA. Comparison of the efficacy of administering a combination of ezetimibe plus fenofibrate versus atorvastatin monotherapy in the treatment of dyslipidemia. Lipids Health Disease Journal. 2009; 8:56.doi:10.1186/1476-511X-8-56.
7. Lemke TL, Williams DA, Roche VF, Zito WS (Ed). Foye’s Principles of Medicinal Chemistry, 7th edition, Chapter 25, antihyperlipoproteinemics and inhibitors of cholesterol biosynthesis, Wolters Kluwer; Lippincott Williams and Wilkins, 2013; pp. 827-837.
8. CIMS (Current Index of Medical Specialities), UBM Medica India Pvt. Limited, Bangalore, pp. 140-142, Jan. – Apr. (2016).
9. Patel A, Macwana C, Parmar V, Patel S. Simultaneous determination of atorvastatin calcium, ezetimibe, and fenofibrate in a tablet formulation by HPLC. Journal of AOAC International. 2012; 95(2):419-423.
10. Choudhari VP and Nikalje AP. Simultaneous Estimation of Atorvastatin, Ezetimibe and Fenofibrate in Pharmaceutical Formulation by RP-LC-PDA. Pharmaceutica Analytica Acta Journal. 2010; 1:111.doi:10.4172/2153- 2435.1000111.
11. Abhijit DD, Padmanabh DB, Santosh GV, Sujith N, Suvarna V. A Simple and Sensitive RP-HPLC Method for Simultaneous Estimation of Atorvastatin Calcium, Ezetimibe and Fenofibrate in Combined Tablet Dosage Form. Research Journal of Pharmacy and Technology. 2013; 6(10):1085-1088.